Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1999, p. 2484-2492, Vol. 43, No. 10
Service des Maladies Infectieuses et
Tropicales,
Received 25 September 1998/Returned for modification 20 February
1999/Accepted 16 June 1999
The increase of penicillin-resistant Streptococcus
pneumoniae (PRSP) pneumonia results in a greater risk of
antibiotic treatment failure. In vitro data are not sufficient
predictors of clinical efficacy, and animal models may be
insufficiently contributive, since they often use immunocompromised
animals and do not always respect the human pharmacokinetics of
antibiotics. We developed an experimental PRSP pneumonia model in
immunocompetent rabbits, by using intrabronchial instillation of PRSP
(MIC = 4 mg/liter), without any adjuvant. This reproducible model
was used to assess amoxicillin efficacy by reproducing human serum
pharmacokinetics following 1-g oral or intravenous administrations of
amoxicillin every 8 h. Evaluation was performed by using clinical,
CT scan, macroscopic, histopathologic, and microbiological criteria.
Experimental pneumonia in untreated rabbits was similar to untreated
severe human bacteremic untreated pneumonia; in both rabbits and
humans, (i) cumulative survival was close to 50%, (ii) red or gray
lung congestion and pleuritis were observed, and (iii) lung and spleen concentrations reached 5 and 4 log10 CFU/g. A 48-h
treatment resulted in a significant bacterial clearance in the lungs
(1.53 versus 5.07 log10 CFU/ml, P < 0.001) and spleen (1.00 versus 4.40 log10 CFU/ml,
P < 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Development of a New Experimental Model of Penicillin-Resistant
Streptococcus pneumoniae Pneumonia and Amoxicillin
Treatment by Reproducing Human Pharmacokinetics
6) and a significant decrease in
mortality (0% versus 50%, P = 0.02) in treated
versus untreated rabbits. No difference was observed on macroscopic and
histopathologic lesions between treated and untreated rabbits
(P = 0.36 and 0.78, respectively). Similar results were obtained by using a fully penicillin-susceptible S. pneumoniae strain (MIC = 0.01 mg/liter). Our findings
suggest that (i) this new model can be contributive in the evaluation
of antibacterial agents and (ii) 1 g of amoxicillin three times a
day may be sufficient to treat PRSP pneumonia in immunocompetent humans.
*
Corresponding author. Mailing address: Service des
Maladies Infectieuses et Tropicales, Hôpital du Bocage, BP 1542, 21034 Dijon Cedex, France. Phone: (33) 3 80 29 36 37. Fax: (33) 3 80 29 36 38. E-mail: p.chavanet{at}planetb.fr.
Antimicrobial Agents and Chemotherapy, October 1999, p. 2484-2492, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |